ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

GlaxoSmithKline: Complied With Indian Rules In Getting Heart, Lung Drug Approved

BANGALORE -(Dow Jones)- GlaxoSmithKline PLC (GSK) said Thursday the company was granted a waiver on conducting clinical trials in India for ambrisentan, its drug to treat pulmonary arterial hypertension, as local rules allow such a concession for drugs to treat a "rare disease which is life threatening and debilitating." The multinational drug maker's comments come in response to an Indian parliamentary panel report that said the heart and lung drug was among the medicines that were approved for sale by the country's drug regulator without mandatory final-stage clinical trials being conducted. The report, tabled in parliament Tuesday, pulled up the Central Drugs Standard Control Organization for irregularities in approving certain drugs as it had failed to obtain scientific evidence to establish their effectiveness and safety profile in treating Indian patients. It also alleged collusion among drug makers, experts like private and government doctors and CDSCO officials in the granting of approvals to certain drugs in the country. In addition to GlaxoSmithKline's ambrisentan, the report named some drugs made by Novartis AG (NOVN.VX), Eli Lilly & Co. (LLY) and India's Cipla Ltd. (500087.BY) as being approved for sale in India without trials. Ambrisentan was approved in Europe in 2008 and in the U.S. in 2007 and is currently available in 43 countries worldwide, a GlaxoSmithKline spokesman said in a statement. The company added that it had submitted the complete global clinical data set to regulatory authorities in India in 2009 and that ambrisentan gained marketing approval in the country in 2010. -By Rumman Ahmed, Dow Jones Newswires; 91-9845104173; rumman.ahmed@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
07/02/201503:48:47Ergomed Appoints Andrew Mackie as Chief Business Officer
06/29/201517:51:48ADRs End Lower; National Bank of Greece Drops Sharply
06/29/201503:39:07Novartis Buys Drug Development Company Spinifex Pharmaceuticals
06/24/201511:22:00Hagens Berman: Class Action Alleges Novartis Gleevec Patent Infringement...
06/22/201518:35:21ADRs End Higher; National Bank of Greece Rises
06/22/201507:47:44GlaxoSmithKline Sells Meningitis Vaccines to Pfizer For EUR115...
06/21/201511:06:03What Is Cancer Immunotherapy?
06/19/201511:38:07Novartis CEO: Roche Stake Would No Longer Have to Be Sold at...
06/18/201518:40:20ADRs End Higher; Telecom Italia Rises
06/18/201515:50:25Teva's Copaxone Patent Loses Again
06/17/201509:04:025 Healthcare Stocks for Dividend Lovers
06/14/201508:03:023 Big Healthcare Trends Wall Street Is Overlooking
06/13/201507:18:021 Drug Will Make or Break These 3 Biotech Stocks
06/10/201510:05:06Cancer Stocks: 2 to Sell, 1 to Buy
06/10/201510:05:06Cancer Stocks: 2 to Sell, 1 to Buy
06/10/201508:04:03Stocks to Watch in Animal Health: Zoetis and WOOF Lead the Pack
06/08/201519:01:02Google Inc Founder Sergey Brin Defends "Moonshots" to Shareholders
06/08/201507:24:023 Big Pharma Dividend Stocks That Are Dragging Down Your Returns
05/31/201513:03:02Stocks To Watch in Biotech
05/31/201510:19:03Why AbbVie, Inc. Is a Better Long-Term Buy Than Gilead Sciences...

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad